arm injection site for semaglutide glp1 sites Semaglutide Arm Injections: Proper Technique

Back to Journals Diabetes, Metabolic Syndrome and Obesity Volume 19 Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations Authors Ylmaz N , Bastemir M Received 27 November 2025 Accepted for publication 13 January 2026 Published 30 January 2026 Volume 2026:19 584175 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Dr Halis Akturk Nimet Ylmaz, 1 Mehmet Bastemir 2 1 Department of Gastroenterology, SANKO University Faculty of Medicine, Gaziantep, Turkey

Stool testing, hydration status, and exposure history guide care

According to the Summary of Product Characteristics (SmPCs), GLP-1 medications commonly cause nausea (reported in approximately 20-40% of patients with semaglutide and 12-21% with dulaglutide), vomiting, and diarrhoea, particularly during initial treatment and dose escalation

Repair cells move by building and releasing an internal scaffold made from actin

Herbal preparations that affect blood glucose levels, such as ginseng, fenugreek, or bitter melon, may have additive glucose-lowering effects when combined with semaglutide, potentially increasing the risk of hypoglycemia particularly in patients receiving other antidiabetic medications

I think Retatrutide has unique potential for women approaching pregnancy in the 6-18 month timeframe